Molecular portraits of numerous tumors have flooded oncologists with vast amounts of data. In parallel, effective inhibitors of central pathways have shown great clinical benefit. Together, this promises potential clinical benefit to otherwise end-stage cancer patients.
Here, we report a clinical service offering mutation detection of archived samples using the ion Ampliseq™ cancer panel coupled with clinical consultation. A multidisciplinary think tank consisting of cancer-biologists, genetic counselors, oncologists, and pathologists discussed 67 patient cases, taking into account the identified mutations, the case history and relevant literature.
The team generated a treatment plan, targeting specific mutations, for 41 out of 64 cases. Three patients died before results were available. For 32 patients, the treating oncologists chose not to include the panel recommendation in the treatment plan for various reasons. Nine patients were treated as recommended by the panel, five with clinical benefit and four with disease progression.
This study suggests that routine use of massive parallel tumor sequencing is feasible and can judiciously affect treatment decisions when coupled with multidisciplinary team-based decision making. Administration of personally based therapies at an earlier stage of therapy, expansion of genetic alterations examined and increased availability of biological therapies may lead to further improvement in the clinical outcome of patients.
Clinical trial identification
Legal entity responsible for the study
Hadassah Medical Organization
Hadassah Medical Center
All authors have declared no conflicts of interest.